We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Zevra Therapeutics (ZVRA - Free Report) shares ended the last trading session 6.6% higher at $6.14. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1% loss over the past four weeks.
The sudden surge in the stock price can be attributed to the positive investor mindset regarding the company's pipeline candidates. Zevra's new drug application for arimoclomol, to treat Niemann-Pick disease type C, is currently under review with the FDA. A decision from the regulatory body is expected in June 2024. The company's commercial portfolio currently comprises its only marketed product in the United States, Azstarys, for the treatment of attention deficit hyperactivity disorder in patients aged six years and older.
This specialty pharmaceutical company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +26.9%. Revenues are expected to be $13.52 million, up 482.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Zevra Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZVRA going forward to see if this recent jump can turn into more strength down the road.
Zevra Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, OptiNose (OPTN - Free Report) , finished the last trading session 6.3% higher at $1.35. OPTN has returned 0% over the past month.
For OptiNose, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.10. This represents a change of +41.2% from what the company reported a year ago. OptiNose currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
Zevra Therapeutics (ZVRA - Free Report) shares ended the last trading session 6.6% higher at $6.14. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1% loss over the past four weeks.
The sudden surge in the stock price can be attributed to the positive investor mindset regarding the company's pipeline candidates. Zevra's new drug application for arimoclomol, to treat Niemann-Pick disease type C, is currently under review with the FDA. A decision from the regulatory body is expected in June 2024. The company's commercial portfolio currently comprises its only marketed product in the United States, Azstarys, for the treatment of attention deficit hyperactivity disorder in patients aged six years and older.
This specialty pharmaceutical company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +26.9%. Revenues are expected to be $13.52 million, up 482.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Zevra Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZVRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zevra Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, OptiNose (OPTN - Free Report) , finished the last trading session 6.3% higher at $1.35. OPTN has returned 0% over the past month.
For OptiNose, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.10. This represents a change of +41.2% from what the company reported a year ago. OptiNose currently has a Zacks Rank of #3 (Hold).